title: [Paradigm shift and future perspectives in rheumatoid arthritis].
abstract: Introduction of methotrexate (MTX) and biologic agents caused a paradigm shift in the treatment of rheumatoid arthritis(RA). Development of new classification criteria for RA was established in 2010, which makes early diagnosis of RA possible. Treating to target (T2T) by setting treatment goal avoids irreversible joint damage and disability in RA. Remission, thus became a realistic goal with early diagnosis and intervention. Consequently, not only clinical but also structural and functional remission can be achieved with the current treatment. However, risk managements with the use of these agents are also of importance. In addition, there remains unmet needs in RA treatment.
authors: Department of Medicine & Rheumatology, Tokyo Medical & Dental University.
authors: Nobuyuki
authors: N
authors: Miyasaka
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods; D042241:Early Diagnosis; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate